Denali Therapeutics Inc (DNLI)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$13.14

Buy

$14.00

arrow-down$-0.38 (-2.68%)

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Prices updated at 16 May 2025, 23:51 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.52%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Vicki L. Sato, PhD
CEO
Dr. Ryan J. Watts, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
443
Head office
161 Oyster Point Boulevard
South San Francisco
United States
94080
mobile
+1 650 866-8547
letter
contact@dnli.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Jay T. Flatley
Independent Director
0.07m--0.38m-
Mr. Julian C. Baker
Independent Director
-----
Dr. Marc Tessier-Lavigne, PhD
Independent Director
0.06m--0.37m-
Dr. Vicki L. Sato, PhD
Chairman of the Board
0.09m--0.40m-
Mr. Peter S. Klein
Independent Director
0.07m--0.39m-
Dr. David P. Schenkein, M.D.
Independent Director
0.07m--0.38m-
Mr. Steven E. Krognes
Director
0.05m--0.36m-
Dr. Ryan J. Watts, PhD
Director, President and Chief Executive Officer
0.69m0.63m-6.56m-
Dr. Alexander O. Schuth, M.D.
Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
0.54m0.34m-4.02m-
Dr. Carole Ho, M.D.
Chief Medical Officer and Head of Development
0.54m0.34m-4.02m-
Ms. Jennifer E. Cook
Independent Director
0.06m--0.37m-
Mr. Erik Harris
Independent Director
0.06m--0.37m-
Ms. Nancy A. Thornberry
Independent Director
0.06m--0.37m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock, Inc.13,787,873-13787873-30 Apr 20259.58
BlackRock Inc13,834,9560.00395-85289-0.61269830 Apr 20259.52
Baillie Gifford & Co Limited.12,090,0400.14344-223891-1.81819330 Apr 20258.32
Vanguard Group Inc11,799,7570.0029-221473-1.84234930 Apr 20258.12
Wellington Management Company LLP11,409,5980.02984156164715.85758330 Apr 20257.85

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
31 Dec 2024-Mr. Steven E. Krognes20.25607,50029,096--
27 Dec 2024-Dr. Alexander O. Schuth, M.D.5.2835,418205,290--
27 Dec 2024-Dr. Alexander O. Schuth, M.D.--46,671--
25 Nov 2024-Dr. Carole Ho, M.D.--107,155--
25 Nov 2024-Dr. Carole Ho, M.D.0.6812,135136,655--
22 Nov 2024-Dr. Alexander O. Schuth, M.D.--124,562--
22 Nov 2024-Dr. Alexander O. Schuth, M.D.0.6813,951198,582--
11 Nov 2024-Dr. David P. Schenkein, M.D.18.00848,97068,661--
11 Nov 2024-Dr. David P. Schenkein, M.D.-----
11 Nov 2024-Dr. David P. Schenkein, M.D.32.871,062,0959,220--
11 Nov 2024-Dr. David P. Schenkein, M.D.32.09870,57041,532--
07 Nov 2024-Dr. Vicki L. Sato, PhD30.0030,600111,056--
07 Nov 2024-Dr. Alexander O. Schuth, M.D.5.2882,146193,624--
07 Nov 2024-Dr. Alexander O. Schuth, M.D.--53,379--
07 Nov 2024-Dr. Alexander O. Schuth, M.D.31.299,387178,066--
07 Nov 2024-Dr. Alexander O. Schuth, M.D.30.7289,856178,366--
07 Nov 2024-Dr. Alexander O. Schuth, M.D.29.68366,043181,291--
01 Nov 2024-Dr. Vicki L. Sato, PhD27.0783,376112,076--
18 Oct 2024-Dr. Ryan J. Watts, PhD27.691,107,600235,807--
18 Oct 2024-Dr. Ryan J. Watts, PhD--1,078,091--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.